在癌症中治疗术后胃肠道功能障碍的针:系统性审查和元分析
Dezhi Lin1, Yangxu Ou1, Longlong Li1
1School of Acupuncture and Tuina, Chengdu University of Traditional Chinese Medicine, Chengdu, China.
Frontiers in oncology
|June 26, 2023
概括
针有效地减少了癌症患者术后胃肠功能障碍的第一次浮和排便的时间. 这种治疗方法是安全的,并且有望改善手术后的康复.
科学领域:
- 在瘤学瘤学.
- 胃肠病学 胃肠病学
- 综合医学是一个整体医学.
背景情况:
- 手术后的胃肠功能障碍 (PGD) 是癌症患者经常发生的严重并发症.
- 针是一种常用的干预措施,用于管理PGD在这个人群.
- 针治疗癌症患者的PGD的疗效和安全性需要系统评估.
研究的目的:
- 评估针治疗癌症患者术后胃肠功能障碍 (PGD) 的疗效和安全性.
- 综合来自随机对照试验 (RCT) 关于针治疗癌症中的PGD的证据.
- 评估针对重点康复指标和患者结果的影响.
主要方法:
- 在2022年11月之前发布的RCT的八个数据库中进行了全面的文献搜索.
- 主要结局包括时间到第一次浮气 (TFF) 和时间到第一次排便 (TFD).
- 二级结局是肠道声音恢复的时间 (TBSR) 和住院时间 (LOS).
- 使用Cochrane协作和GRADE系统分别评估了偏见风险和证据确定性.
- 使用RevMan 5.4进行了元分析,使用Stata 15.1.1测试了出版偏差.
主要成果:
- 分析了涉及877名参与者的16个RCT.
- 与常规治疗,假和手术后增强恢复 (ERAS) 相比,针显著降低了TFF,TFD和TBSR.
- 与常规治疗和ERAS相比,在住院时间 (LOS) 中没有发现显著差异.
- 亚组分析证实了各种癌症类型和针点组合的TFF和TFD减少.
- 在包括的试验中,没有报告与针相关的不良事件.
结论:
- 针证明了在癌症患者中管理PGD的有效性和有利的安全性.
- 建议进一步进行高质量的RCT,以探索在各种癌症类型中用于PGD的各种针技术和组合.
- 需要进一步的研究来验证这些发现在中国以外的人口.
更多相关视频
03:50Acupoint Application Combined with Acupoint Massage for Treating Constipation in a Patient with Chronic Obstructive Pulmonary Disease
Published on: August 18, 2023
1.9K
05:56Acupoint Application Combined with Acupressure as an Adjunctive Therapy for Chemotherapy-Induced Nausea and Vomiting
Published on: June 21, 2024
913
相关概念视频
Endoscopic Procedures IV: Sigmoidoscopy and Laproscopy
126
Sigmoidoscopy and laparoscopy are distinct medical procedures that enable physicians to internally inspect different parts of the GI tract. Although they serve different purposes, each is essential for diagnosing and, in some cases, treating various medical conditions.
Sigmoidoscopy
Sigmoidoscopy is a diagnostic procedure that uses a flexible sigmoidoscope equipped with a light source and camera to examine the rectum and sigmoid colon. The procedure involves inserting the tube through the anus...
Sigmoidoscopy
Sigmoidoscopy is a diagnostic procedure that uses a flexible sigmoidoscope equipped with a light source and camera to examine the rectum and sigmoid colon. The procedure involves inserting the tube through the anus...
126
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
208
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
208
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
251
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
251
